Investors considering a purchase of Kymera Therapeutics Inc (KYMR) shares, but cautious about paying the going market price of 22.35/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the December...

WATERTOWN, Mass., June 22, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the U.S. Food and Drug Administration (FDA...

Data shared today on PK/PD and safety from additional KT-333 and KT-413 patient dose escalation cohorts show target knockdown at or near levels associated with clinical efficacy in preclinical tumor models No dose limiting toxicities observed in either program KT-333 data will be presented in a ...

A single dose of KT-253 drives tumor regression and demonstrates differentiated pharmacology compared to small molecule inhibitor (SMI) in preclinical models of ALL and AMLWATERTOWN, Mass., June 09, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical...

In trading on Thursday, shares of Kymera Therapeutics Inc (KYMR) crossed below their 200 day moving average of 29.07, changing hands as low as 26.43 per share. Kymera Therapeutics Inc shares are currently trading down about 13.4% on the day...